#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. What do the Clinical Data Teach Us ?
1-1	0-2	6.	_	_	_	_
1-2	3-7	What	_	_	_	_
1-3	8-10	do	_	_	_	_
1-4	11-14	the	organization[1]	new[1]	_	_
1-5	15-23	Clinical	organization[1]	new[1]	_	_
1-6	24-28	Data	organization[1]	new[1]	_	_
1-7	29-34	Teach	_	_	_	_
1-8	35-37	Us	person	acc	_	_
1-9	38-39	?	_	_	_	_

#Text=As discussed above , the great majority of the radiobiological investigations have been done with very radioresistant and hyper-radiosensitive cells .
2-1	40-42	As	_	_	_	_
2-2	43-52	discussed	_	_	_	_
2-3	53-58	above	_	_	_	_
2-4	59-60	,	_	_	_	_
2-5	61-64	the	abstract[3]	new[3]	_	_
2-6	65-70	great	abstract[3]	new[3]	_	_
2-7	71-79	majority	abstract[3]	new[3]	_	_
2-8	80-82	of	abstract[3]	new[3]	_	_
2-9	83-86	the	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-10	87-102	radiobiological	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-11	103-117	investigations	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-12	118-122	have	_	_	_	_
2-13	123-127	been	_	_	_	_
2-14	128-132	done	_	_	_	_
2-15	133-137	with	_	_	_	_
2-16	138-142	very	object[5]	new[5]	coref	9-3[46_5]
2-17	143-157	radioresistant	object[5]	new[5]	_	_
2-18	158-161	and	object[5]	new[5]	_	_
2-19	162-182	hyper-radiosensitive	object[5]	new[5]	_	_
2-20	183-188	cells	object[5]	new[5]	_	_
2-21	189-190	.	_	_	_	_

#Text=However , the hyper-radiosensitive and hyper-radioresistant cellular models are not representative of the clinical reality .
3-1	191-198	However	_	_	_	_
3-2	199-200	,	_	_	_	_
3-3	201-204	the	abstract[6]	new[6]	coref	16-9[111_6]
3-4	205-225	hyper-radiosensitive	abstract[6]	new[6]	_	_
3-5	226-229	and	abstract[6]	new[6]	_	_
3-6	230-250	hyper-radioresistant	abstract[6]	new[6]	_	_
3-7	251-259	cellular	abstract[6]	new[6]	_	_
3-8	260-266	models	abstract[6]	new[6]	_	_
3-9	267-270	are	_	_	_	_
3-10	271-274	not	_	_	_	_
3-11	275-289	representative	_	_	_	_
3-12	290-292	of	_	_	_	_
3-13	293-296	the	abstract[7]	new[7]	_	_
3-14	297-305	clinical	abstract[7]	new[7]	_	_
3-15	306-313	reality	abstract[7]	new[7]	_	_
3-16	314-315	.	_	_	_	_

#Text=For example , there is no known human genetic syndromes caused by mutations of Ku or DNA-PKcs proteins , the major NHEJ actors .
4-1	316-319	For	_	_	_	_
4-2	320-327	example	_	_	_	_
4-3	328-329	,	_	_	_	_
4-4	330-335	there	_	_	_	_
4-5	336-338	is	_	_	_	_
4-6	339-341	no	abstract[8]	new[8]	coref	10-12[53_8]
4-7	342-347	known	abstract[8]	new[8]	_	_
4-8	348-353	human	abstract[8]	new[8]	_	_
4-9	354-361	genetic	abstract[8]	new[8]	_	_
4-10	362-371	syndromes	abstract[8]	new[8]	_	_
4-11	372-378	caused	abstract[8]	new[8]	_	_
4-12	379-381	by	abstract[8]	new[8]	_	_
4-13	382-391	mutations	abstract[8]|abstract[9]	new[8]|new[9]	_	_
4-14	392-394	of	abstract[8]|abstract[9]	new[8]|new[9]	_	_
4-15	395-397	Ku	abstract[8]|abstract[9]|person	new[8]|new[9]|new	coref	16-27
4-16	398-400	or	abstract[8]|abstract[9]	new[8]|new[9]	_	_
4-17	401-409	DNA-PKcs	abstract[8]|abstract[9]|abstract|substance[12]	new[8]|new[9]|new|new[12]	coref|coref	10-5[51_12]|16-29[117_0]
4-18	410-418	proteins	abstract[8]|abstract[9]|substance[12]	new[8]|new[9]|new[12]	_	_
4-19	419-420	,	_	_	_	_
4-20	421-424	the	person[14]	new[14]	_	_
4-21	425-430	major	person[14]	new[14]	_	_
4-22	431-435	NHEJ	abstract|person[14]	new|new[14]	coref	5-9
4-23	436-442	actors	person[14]	new[14]	_	_
4-24	443-444	.	_	_	_	_

#Text=The only human case of gross defect in NHEJ function to non-viability was caused by mutations of DNA ligase IV ( LIG4 ) .
5-1	445-448	The	event[15]	new[15]	_	_
5-2	449-453	only	event[15]	new[15]	_	_
5-3	454-459	human	event[15]	new[15]	_	_
5-4	460-464	case	event[15]	new[15]	_	_
5-5	465-467	of	event[15]	new[15]	_	_
5-6	468-473	gross	event[15]|abstract[16]	new[15]|new[16]	coref	13-9[80_16]
5-7	474-480	defect	event[15]|abstract[16]	new[15]|new[16]	_	_
5-8	481-483	in	event[15]|abstract[16]	new[15]|new[16]	_	_
5-9	484-488	NHEJ	event[15]|abstract[16]|abstract|abstract[18]	new[15]|new[16]|giv|new[18]	coref	16-32
5-10	489-497	function	event[15]|abstract[16]|abstract[18]	new[15]|new[16]|new[18]	_	_
5-11	498-500	to	event[15]|abstract[16]	new[15]|new[16]	_	_
5-12	501-514	non-viability	event[15]|abstract[16]	new[15]|new[16]	_	_
5-13	515-518	was	_	_	_	_
5-14	519-525	caused	_	_	_	_
5-15	526-528	by	_	_	_	_
5-16	529-538	mutations	abstract[19]	new[19]	coref	6-24[31_19]
5-17	539-541	of	abstract[19]	new[19]	_	_
5-18	542-545	DNA	abstract[19]|abstract|substance[21]	new[19]|new|new[21]	_	_
5-19	546-552	ligase	abstract[19]|substance[21]	new[19]|new[21]	_	_
5-20	553-555	IV	abstract[19]|substance[21]	new[19]|new[21]	_	_
5-21	556-557	(	_	_	_	_
5-22	558-562	LIG4	abstract	new	coref	14-17
5-23	563-564	)	_	_	_	_
5-24	565-566	.	_	_	_	_

#Text=The majority of cases of fatal post-radiotherapy events were encountered after whole-body irradiation of children with ataxia telangiectasia ( AT ) caused by homozygous ATM mutations during their anti-leukemia or lymphoma treatment .
6-1	567-570	The	event[23]	new[23]	_	_
6-2	571-579	majority	event[23]	new[23]	_	_
6-3	580-582	of	event[23]	new[23]	_	_
6-4	583-588	cases	event[23]	new[23]	_	_
6-5	589-591	of	event[23]	new[23]	_	_
6-6	592-597	fatal	event[23]|event[24]	new[23]|new[24]	_	_
6-7	598-615	post-radiotherapy	event[23]|event[24]	new[23]|new[24]	_	_
6-8	616-622	events	event[23]|event[24]	new[23]|new[24]	_	_
6-9	623-627	were	_	_	_	_
6-10	628-639	encountered	_	_	_	_
6-11	640-645	after	_	_	_	_
6-12	646-656	whole-body	event[25]	new[25]	coref	20-18[0_25]
6-13	657-668	irradiation	event[25]	new[25]	_	_
6-14	669-671	of	event[25]	new[25]	_	_
6-15	672-680	children	event[25]|person[26]	new[25]|new[26]	ana	6-28[0_26]
6-16	681-685	with	event[25]|person[26]	new[25]|new[26]	_	_
6-17	686-692	ataxia	event[25]|person[26]|animal|abstract[28]	new[25]|new[26]|new|new[28]	appos	6-20[0_28]
6-18	693-707	telangiectasia	event[25]|person[26]|abstract[28]	new[25]|new[26]|new[28]	_	_
6-19	708-709	(	event[25]|person[26]	new[25]|new[26]	_	_
6-20	710-712	AT	event[25]|person[26]|abstract	new[25]|new[26]|giv	_	_
6-21	713-714	)	event[25]|person[26]	new[25]|new[26]	_	_
6-22	715-721	caused	event[25]|person[26]	new[25]|new[26]	_	_
6-23	722-724	by	event[25]|person[26]	new[25]|new[26]	_	_
6-24	725-735	homozygous	event[25]|person[26]|abstract[31]	new[25]|new[26]|giv[31]	coref	10-7[52_31]
6-25	736-739	ATM	event[25]|person[26]|object|abstract[31]	new[25]|new[26]|new|giv[31]	coref	14-20
6-26	740-749	mutations	event[25]|person[26]|abstract[31]	new[25]|new[26]|giv[31]	_	_
6-27	750-756	during	event[25]|person[26]	new[25]|new[26]	_	_
6-28	757-762	their	event[25]|person[26]|person|event[33]	new[25]|new[26]|giv|new[33]	ana	7-1[0_33]
6-29	763-776	anti-leukemia	event[25]|person[26]|event[33]	new[25]|new[26]|new[33]	_	_
6-30	777-779	or	event[25]|person[26]|event[33]	new[25]|new[26]|new[33]	_	_
6-31	780-788	lymphoma	event[25]|person[26]|event[33]	new[25]|new[26]|new[33]	_	_
6-32	789-798	treatment	event[25]|person[26]|event[33]	new[25]|new[26]|new[33]	_	_
6-33	799-800	.	_	_	_	_

#Text=It is important to note that AT frequency is of about 1/100,000 .
7-1	801-803	It	event	giv	_	_
7-2	804-806	is	_	_	_	_
7-3	807-816	important	_	_	_	_
7-4	817-819	to	_	_	_	_
7-5	820-824	note	_	_	_	_
7-6	825-829	that	_	_	_	_
7-7	830-832	AT	_	_	_	_
7-8	833-842	frequency	abstract	new	_	_
7-9	843-845	is	_	_	_	_
7-10	846-848	of	_	_	_	_
7-11	849-854	about	abstract[36]	new[36]	_	_
7-12	855-864	1/100,000	abstract[36]	new[36]	_	_
7-13	865-866	.	_	_	_	_

#Text=By contrast , about 5 % – 20 % cancer of patients treated by radiotherapy exhibit post-radiotherapy tissue reactions that can be considered as moderate radiosensitivity .
8-1	867-869	By	_	_	_	_
8-2	870-878	contrast	abstract	new	coref	24-2
8-3	879-880	,	_	_	_	_
8-4	881-886	about	abstract[39]	new[39]	coref	11-12[0_39]
8-5	887-888	5	abstract[39]	new[39]	_	_
8-6	889-890	%	abstract[39]	new[39]	_	_
8-7	891-892	–	abstract[39]	new[39]	_	_
8-8	893-895	20	abstract[39]	new[39]	_	_
8-9	896-897	%	abstract|abstract[39]	new|new[39]	_	_
8-10	898-904	cancer	abstract[39]	new[39]	_	_
8-11	905-907	of	abstract[39]	new[39]	_	_
8-12	908-916	patients	abstract[39]|person[40]	new[39]|new[40]	_	_
8-13	917-924	treated	abstract[39]|person[40]	new[39]|new[40]	_	_
8-14	925-927	by	abstract[39]|person[40]	new[39]|new[40]	_	_
8-15	928-940	radiotherapy	abstract[39]|person[40]|abstract	new[39]|new[40]|new	_	_
8-16	941-948	exhibit	_	_	_	_
8-17	949-966	post-radiotherapy	event[43]	new[43]	_	_
8-18	967-973	tissue	object|event[43]	new|new[43]	_	_
8-19	974-983	reactions	event[43]	new[43]	_	_
8-20	984-988	that	event[43]	new[43]	_	_
8-21	989-992	can	event[43]	new[43]	_	_
8-22	993-995	be	event[43]	new[43]	_	_
8-23	996-1006	considered	event[43]	new[43]	_	_
8-24	1007-1009	as	event[43]	new[43]	_	_
8-25	1010-1018	moderate	event[43]|abstract[44]	new[43]|new[44]	coref	9-10[47_44]
8-26	1019-1035	radiosensitivity	event[43]|abstract[44]	new[43]|new[44]	_	_
8-27	1036-1037	.	_	_	_	_

#Text=Surprisingly , no or very few rodent cells with moderate radiosensitivity have been the subject of a published radiobiological characterization .
9-1	1038-1050	Surprisingly	_	_	_	_
9-2	1051-1052	,	_	_	_	_
9-3	1053-1055	no	object[46]	giv[46]	coref	9-14[48_46]
9-4	1056-1058	or	object[46]	giv[46]	_	_
9-5	1059-1063	very	object[46]	giv[46]	_	_
9-6	1064-1067	few	object[46]	giv[46]	_	_
9-7	1068-1074	rodent	animal|object[46]	new|giv[46]	_	_
9-8	1075-1080	cells	object[46]	giv[46]	_	_
9-9	1081-1085	with	object[46]	giv[46]	_	_
9-10	1086-1094	moderate	object[46]|abstract[47]	giv[46]|giv[47]	coref	11-23[62_47]
9-11	1095-1111	radiosensitivity	object[46]|abstract[47]	giv[46]|giv[47]	_	_
9-12	1112-1116	have	_	_	_	_
9-13	1117-1121	been	_	_	_	_
9-14	1122-1125	the	object[48]	giv[48]	ana	10-3[50_48]
9-15	1126-1133	subject	object[48]	giv[48]	_	_
9-16	1134-1136	of	object[48]	giv[48]	_	_
9-17	1137-1138	a	object[48]|abstract[49]	giv[48]|new[49]	_	_
9-18	1139-1148	published	object[48]|abstract[49]	giv[48]|new[49]	_	_
9-19	1149-1164	radiobiological	object[48]|abstract[49]	giv[48]|new[49]	_	_
9-20	1165-1181	characterization	object[48]|abstract[49]	giv[48]|new[49]	_	_
9-21	1182-1183	.	_	_	_	_

#Text=Interestingly , some of the proteins whose mutations are responsible for these syndromes were cited as components of the different variants of A-NHEJ ( see Section 4 ) .
10-1	1184-1197	Interestingly	_	_	_	_
10-2	1198-1199	,	_	_	_	_
10-3	1200-1204	some	object[50]	giv[50]	coref	14-17[90_50]
10-4	1205-1207	of	object[50]	giv[50]	_	_
10-5	1208-1211	the	object[50]|substance[51]	giv[50]|giv[51]	coref	12-13[73_51]
10-6	1212-1220	proteins	object[50]|substance[51]	giv[50]|giv[51]	_	_
10-7	1221-1226	whose	object[50]|substance[51]|abstract[52]	giv[50]|giv[51]|giv[52]	_	_
10-8	1227-1236	mutations	object[50]|substance[51]|abstract[52]	giv[50]|giv[51]|giv[52]	_	_
10-9	1237-1240	are	object[50]|substance[51]	giv[50]|giv[51]	_	_
10-10	1241-1252	responsible	object[50]|substance[51]	giv[50]|giv[51]	_	_
10-11	1253-1256	for	object[50]|substance[51]	giv[50]|giv[51]	_	_
10-12	1257-1262	these	object[50]|substance[51]|abstract[53]	giv[50]|giv[51]|giv[53]	coref	11-4[58_53]
10-13	1263-1272	syndromes	object[50]|substance[51]|abstract[53]	giv[50]|giv[51]|giv[53]	_	_
10-14	1273-1277	were	_	_	_	_
10-15	1278-1283	cited	_	_	_	_
10-16	1284-1286	as	_	_	_	_
10-17	1287-1297	components	abstract[54]	new[54]	_	_
10-18	1298-1300	of	abstract[54]	new[54]	_	_
10-19	1301-1304	the	abstract[54]|abstract[55]	new[54]|new[55]	_	_
10-20	1305-1314	different	abstract[54]|abstract[55]	new[54]|new[55]	_	_
10-21	1315-1323	variants	abstract[54]|abstract[55]	new[54]|new[55]	_	_
10-22	1324-1326	of	abstract[54]|abstract[55]	new[54]|new[55]	_	_
10-23	1327-1333	A-NHEJ	abstract[54]|abstract[55]|abstract	new[54]|new[55]|new	_	_
10-24	1334-1335	(	_	_	_	_
10-25	1336-1339	see	_	_	_	_
10-26	1340-1347	Section	abstract[57]	new[57]	_	_
10-27	1348-1349	4	abstract[57]	new[57]	_	_
10-28	1350-1351	)	_	_	_	_
10-29	1352-1353	.	_	_	_	_

#Text=In addition , some genetic syndromes , associated or not with cancer proneness , different from the precited ones , also show a moderate radiosensitivity : this is notably the case of neurofibromatosis , Huntington ’s chorea , and tuberous sclerosis syndromes .
11-1	1354-1356	In	_	_	_	_
11-2	1357-1365	addition	_	_	_	_
11-3	1366-1367	,	_	_	_	_
11-4	1368-1372	some	abstract[58]	giv[58]	coref	11-40[69_58]
11-5	1373-1380	genetic	abstract[58]	giv[58]	_	_
11-6	1381-1390	syndromes	abstract[58]	giv[58]	_	_
11-7	1391-1392	,	abstract[58]	giv[58]	_	_
11-8	1393-1403	associated	abstract[58]	giv[58]	_	_
11-9	1404-1406	or	abstract[58]	giv[58]	_	_
11-10	1407-1410	not	abstract[58]	giv[58]	_	_
11-11	1411-1415	with	abstract[58]	giv[58]	_	_
11-12	1416-1422	cancer	abstract[58]|abstract|abstract[60]	giv[58]|giv|new[60]	coref|coref	24-20|24-20[170_60]
11-13	1423-1432	proneness	abstract[58]|abstract[60]	giv[58]|new[60]	_	_
11-14	1433-1434	,	abstract[58]	giv[58]	_	_
11-15	1435-1444	different	abstract[58]	giv[58]	_	_
11-16	1445-1449	from	_	_	_	_
11-17	1450-1453	the	abstract[61]	new[61]	_	_
11-18	1454-1462	precited	abstract[61]	new[61]	_	_
11-19	1463-1467	ones	abstract[61]	new[61]	_	_
11-20	1468-1469	,	_	_	_	_
11-21	1470-1474	also	_	_	_	_
11-22	1475-1479	show	_	_	_	_
11-23	1480-1481	a	abstract[62]	giv[62]	ana	11-27[0_62]
11-24	1482-1490	moderate	abstract[62]	giv[62]	_	_
11-25	1491-1507	radiosensitivity	abstract[62]	giv[62]	_	_
11-26	1508-1509	:	_	_	_	_
11-27	1510-1514	this	abstract	giv	coref	11-29[64_0]
11-28	1515-1517	is	_	_	_	_
11-29	1518-1525	notably	abstract[64]	giv[64]	ana	12-1[0_64]
11-30	1526-1529	the	abstract[64]	giv[64]	_	_
11-31	1530-1534	case	abstract[64]	giv[64]	_	_
11-32	1535-1537	of	abstract[64]	giv[64]	_	_
11-33	1538-1555	neurofibromatosis	abstract[64]|abstract	giv[64]|new	_	_
11-34	1556-1557	,	abstract[64]	giv[64]	_	_
11-35	1558-1568	Huntington	abstract[64]|person[66]|place[67]	giv[64]|new[66]|new[67]	_	_
11-36	1569-1571	’s	abstract[64]|person[66]|place[67]	giv[64]|new[66]|new[67]	_	_
11-37	1572-1578	chorea	abstract[64]|place[67]	giv[64]|new[67]	_	_
11-38	1579-1580	,	abstract[64]	giv[64]	_	_
11-39	1581-1584	and	abstract[64]	giv[64]	_	_
11-40	1585-1593	tuberous	abstract[64]|abstract[68]|abstract[69]	giv[64]|new[68]|giv[69]	coref	12-6[71_69]
11-41	1594-1603	sclerosis	abstract[64]|abstract[68]|abstract[69]	giv[64]|new[68]|giv[69]	_	_
11-42	1604-1613	syndromes	abstract[64]|abstract[69]	giv[64]|giv[69]	_	_
11-43	1614-1615	.	_	_	_	_

#Text=It must be stressed that these syndromes are caused by mutations of cytoplasmic proteins , which may contradict the historical hypothesis that nucleus is the most radiosensitive part of the cell ( see the Introduction ) .
12-1	1616-1618	It	abstract	giv	coref	13-18[84_0]
12-2	1619-1623	must	_	_	_	_
12-3	1624-1626	be	_	_	_	_
12-4	1627-1635	stressed	_	_	_	_
12-5	1636-1640	that	_	_	_	_
12-6	1641-1646	these	abstract[71]	giv[71]	coref	16-37[119_71]
12-7	1647-1656	syndromes	abstract[71]	giv[71]	_	_
12-8	1657-1660	are	_	_	_	_
12-9	1661-1667	caused	_	_	_	_
12-10	1668-1670	by	_	_	_	_
12-11	1671-1680	mutations	abstract[72]	new[72]	_	_
12-12	1681-1683	of	abstract[72]	new[72]	_	_
12-13	1684-1695	cytoplasmic	abstract[72]|substance[73]	new[72]|giv[73]	_	_
12-14	1696-1704	proteins	abstract[72]|substance[73]	new[72]|giv[73]	_	_
12-15	1705-1706	,	abstract[72]	new[72]	_	_
12-16	1707-1712	which	abstract[72]	new[72]	_	_
12-17	1713-1716	may	abstract[72]	new[72]	_	_
12-18	1717-1727	contradict	abstract[72]	new[72]	_	_
12-19	1728-1731	the	abstract[72]|abstract[74]	new[72]|new[74]	coref	13-6[79_74]
12-20	1732-1742	historical	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-21	1743-1753	hypothesis	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-22	1754-1758	that	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-23	1759-1766	nucleus	abstract[72]|abstract[74]|object	new[72]|new[74]|new	coref	20-31[142_0]
12-24	1767-1769	is	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-25	1770-1773	the	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-26	1774-1778	most	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-27	1779-1793	radiosensitive	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-28	1794-1798	part	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-29	1799-1801	of	abstract[72]|abstract[74]	new[72]|new[74]	_	_
12-30	1802-1805	the	abstract[72]|abstract[74]|object[76]	new[72]|new[74]|new[76]	_	_
12-31	1806-1810	cell	abstract[72]|abstract[74]|object[76]	new[72]|new[74]|new[76]	_	_
12-32	1811-1812	(	_	_	_	_
12-33	1813-1816	see	_	_	_	_
12-34	1817-1820	the	abstract[77]	new[77]	ana	13-3[0_77]
12-35	1821-1833	Introduction	abstract[77]	new[77]	_	_
12-36	1834-1835	)	_	_	_	_
12-37	1836-1837	.	_	_	_	_

#Text=Furthermore , it also contradicts the hypothesis that defect of DSB repair is the unique cause of cellular radiosensitivity .
13-1	1838-1849	Furthermore	_	_	_	_
13-2	1850-1851	,	_	_	_	_
13-3	1852-1854	it	abstract	giv	_	_
13-4	1855-1859	also	_	_	_	_
13-5	1860-1871	contradicts	_	_	_	_
13-6	1872-1875	the	abstract[79]	giv[79]	coref	20-9[137_79]
13-7	1876-1886	hypothesis	abstract[79]	giv[79]	_	_
13-8	1887-1891	that	abstract[79]	giv[79]	_	_
13-9	1892-1898	defect	abstract[79]|abstract[80]|abstract[83]	giv[79]|giv[80]|new[83]	_	_
13-10	1899-1901	of	abstract[79]|abstract[80]|abstract[83]	giv[79]|giv[80]|new[83]	_	_
13-11	1902-1905	DSB	abstract[79]|abstract[80]|abstract|abstract[82]|abstract[83]	giv[79]|giv[80]|new|new[82]|new[83]	coref|coref	14-33|14-34[0_82]
13-12	1906-1912	repair	abstract[79]|abstract[80]|abstract[82]|abstract[83]	giv[79]|giv[80]|new[82]|new[83]	_	_
13-13	1913-1915	is	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-14	1916-1919	the	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-15	1920-1926	unique	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-16	1927-1932	cause	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-17	1933-1935	of	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
13-18	1936-1944	cellular	abstract[79]|abstract[83]|abstract[84]	giv[79]|new[83]|giv[84]	coref	14-24[91_84]
13-19	1945-1961	radiosensitivity	abstract[79]|abstract[83]|abstract[84]	giv[79]|new[83]|giv[84]	_	_
13-20	1962-1963	.	_	_	_	_

#Text=The question of how to build a unified model that would describe both hyper-radiosensitivity observed in LIG4 - and ATM -mutated cells and moderate radiosensitivity caused by impairment of alternative signaling and DSB repair pathways remains .
14-1	1964-1967	The	abstract[85]	new[85]	_	_
14-2	1968-1976	question	abstract[85]	new[85]	_	_
14-3	1977-1979	of	abstract[85]	new[85]	_	_
14-4	1980-1983	how	abstract[85]	new[85]	_	_
14-5	1984-1986	to	abstract[85]	new[85]	_	_
14-6	1987-1992	build	abstract[85]	new[85]	_	_
14-7	1993-1994	a	abstract[85]|abstract[86]	new[85]|new[86]	coref	19-33[130_86]
14-8	1995-2002	unified	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-9	2003-2008	model	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-10	2009-2013	that	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-11	2014-2019	would	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-12	2020-2028	describe	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-13	2029-2033	both	abstract[85]|abstract[86]|abstract[87]	new[85]|new[86]|new[87]	coref	33-37[0_87]
14-14	2034-2056	hyper-radiosensitivity	abstract[85]|abstract[86]|abstract[87]	new[85]|new[86]|new[87]	_	_
14-15	2057-2065	observed	abstract[85]|abstract[86]|abstract[87]	new[85]|new[86]|new[87]	_	_
14-16	2066-2068	in	abstract[85]|abstract[86]|abstract[87]	new[85]|new[86]|new[87]	_	_
14-17	2069-2073	LIG4	abstract[85]|abstract[86]|abstract[87]|abstract|object[90]	new[85]|new[86]|new[87]|giv|giv[90]	coref|coref	24-5[164_90]|33-30
14-18	2074-2075	-	abstract[85]|abstract[86]|abstract[87]|object[90]	new[85]|new[86]|new[87]|giv[90]	_	_
14-19	2076-2079	and	abstract[85]|abstract[86]|abstract[87]|object[90]	new[85]|new[86]|new[87]|giv[90]	_	_
14-20	2080-2083	ATM	abstract[85]|abstract[86]|abstract[87]|object|object[90]	new[85]|new[86]|new[87]|giv|giv[90]	coref	15-5
14-21	2084-2092	-mutated	abstract[85]|abstract[86]|abstract[87]|object[90]	new[85]|new[86]|new[87]|giv[90]	_	_
14-22	2093-2098	cells	abstract[85]|abstract[86]|abstract[87]|object[90]	new[85]|new[86]|new[87]|giv[90]	_	_
14-23	2099-2102	and	abstract[85]|abstract[86]	new[85]|new[86]	_	_
14-24	2103-2111	moderate	abstract[85]|abstract[86]|abstract[91]	new[85]|new[86]|giv[91]	coref	19-24[0_91]
14-25	2112-2128	radiosensitivity	abstract[85]|abstract[86]|abstract[91]	new[85]|new[86]|giv[91]	_	_
14-26	2129-2135	caused	abstract[85]|abstract[86]|abstract[91]	new[85]|new[86]|giv[91]	_	_
14-27	2136-2138	by	abstract[85]|abstract[86]|abstract[91]	new[85]|new[86]|giv[91]	_	_
14-28	2139-2149	impairment	abstract[85]|abstract[86]|abstract[91]|abstract[92]	new[85]|new[86]|giv[91]|new[92]	_	_
14-29	2150-2152	of	abstract[85]|abstract[86]|abstract[91]|abstract[92]	new[85]|new[86]|giv[91]|new[92]	_	_
14-30	2153-2164	alternative	abstract[85]|abstract[86]|abstract[91]|abstract[92]|abstract[93]	new[85]|new[86]|giv[91]|new[92]|new[93]	_	_
14-31	2165-2174	signaling	abstract[85]|abstract[86]|abstract[91]|abstract[92]|abstract[93]	new[85]|new[86]|giv[91]|new[92]|new[93]	_	_
14-32	2175-2178	and	abstract[85]|abstract[86]|abstract[91]|abstract[92]	new[85]|new[86]|giv[91]|new[92]	_	_
14-33	2179-2182	DSB	abstract[85]|abstract[86]|abstract[91]|abstract[92]|abstract|abstract[96]	new[85]|new[86]|giv[91]|new[92]|giv|new[96]	coref	15-16
14-34	2183-2189	repair	abstract[85]|abstract[86]|abstract[91]|abstract[92]|abstract|abstract[96]	new[85]|new[86]|giv[91]|new[92]|giv|new[96]	coref	16-12
14-35	2190-2198	pathways	abstract[85]|abstract[86]|abstract[91]|abstract[92]|abstract[96]	new[85]|new[86]|giv[91]|new[92]|new[96]	_	_
14-36	2199-2206	remains	_	_	_	_
14-37	2207-2208	.	_	_	_	_

#Text=To date , the ATM protein has been considered as an early actor of the DSB recognition via its phosphorylation of H2AX and the individual radiation response .
15-1	2209-2211	To	_	_	_	_
15-2	2212-2216	date	time	new	_	_
15-3	2217-2218	,	_	_	_	_
15-4	2219-2222	the	substance[99]	new[99]	coref	19-10[125_99]
15-5	2223-2226	ATM	object|substance[99]	giv|new[99]	coref	16-3
15-6	2227-2234	protein	substance[99]	new[99]	_	_
15-7	2235-2238	has	_	_	_	_
15-8	2239-2243	been	_	_	_	_
15-9	2244-2254	considered	_	_	_	_
15-10	2255-2257	as	_	_	_	_
15-11	2258-2260	an	person[100]	new[100]	_	_
15-12	2261-2266	early	person[100]	new[100]	_	_
15-13	2267-2272	actor	person[100]	new[100]	_	_
15-14	2273-2275	of	person[100]	new[100]	_	_
15-15	2276-2279	the	person[100]|abstract[102]	new[100]|new[102]	ana	15-19[0_102]
15-16	2280-2283	DSB	person[100]|abstract|abstract[102]	new[100]|giv|new[102]	coref	16-11
15-17	2284-2295	recognition	person[100]|abstract[102]	new[100]|new[102]	_	_
15-18	2296-2299	via	_	_	_	_
15-19	2300-2303	its	abstract|abstract[104]	giv|new[104]	_	_
15-20	2304-2319	phosphorylation	abstract[104]	new[104]	_	_
15-21	2320-2322	of	abstract[104]	new[104]	_	_
15-22	2323-2327	H2AX	abstract[104]|abstract	new[104]|new	coref	21-9
15-23	2328-2331	and	_	_	_	_
15-24	2332-2335	the	abstract[107]	new[107]	coref	19-41[133_107]
15-25	2336-2346	individual	abstract[107]	new[107]	_	_
15-26	2347-2356	radiation	abstract|abstract[107]	new|new[107]	coref	19-43
15-27	2357-2365	response	abstract[107]	new[107]	_	_
15-28	2366-2367	.	_	_	_	_

#Text=Surprisingly , ATM has not been integrated in all the DSB repair models discussed above while mutations of RAD51 and RAD52 ( for HR ) and Ku and DNA-PKcs ( for NHEJ ) do not cause any viable syndromes in humans (
16-1	2368-2380	Surprisingly	_	_	_	_
16-2	2381-2382	,	_	_	_	_
16-3	2383-2386	ATM	object	giv	coref	19-10
16-4	2387-2390	has	_	_	_	_
16-5	2391-2394	not	_	_	_	_
16-6	2395-2399	been	_	_	_	_
16-7	2400-2410	integrated	_	_	_	_
16-8	2411-2413	in	_	_	_	_
16-9	2414-2417	all	abstract[111]	giv[111]	coref	34-26[231_111]
16-10	2418-2421	the	abstract[111]	giv[111]	_	_
16-11	2422-2425	DSB	abstract|abstract[111]	giv|giv[111]	coref	21-12
16-12	2426-2432	repair	abstract|abstract[111]	giv|giv[111]	coref	22-8[154_0]
16-13	2433-2439	models	abstract[111]	giv[111]	_	_
16-14	2440-2449	discussed	abstract[111]	giv[111]	_	_
16-15	2450-2455	above	abstract[111]	giv[111]	_	_
16-16	2456-2461	while	_	_	_	_
16-17	2462-2471	mutations	abstract[112]	new[112]	_	_
16-18	2472-2474	of	abstract[112]	new[112]	_	_
16-19	2475-2480	RAD51	abstract[112]|abstract	new[112]|new	_	_
16-20	2481-2484	and	abstract[112]	new[112]	_	_
16-21	2485-2490	RAD52	abstract[112]|abstract	new[112]|new	_	_
16-22	2491-2492	(	abstract[112]	new[112]	_	_
16-23	2493-2496	for	abstract[112]	new[112]	_	_
16-24	2497-2499	HR	abstract[112]|abstract	new[112]|new	_	_
16-25	2500-2501	)	abstract[112]	new[112]	_	_
16-26	2502-2505	and	abstract[112]	new[112]	_	_
16-27	2506-2508	Ku	abstract[112]|person	new[112]|giv	_	_
16-28	2509-2512	and	abstract[112]	new[112]	_	_
16-29	2513-2521	DNA-PKcs	abstract[112]|abstract[117]	new[112]|giv[117]	_	_
16-30	2522-2523	(	abstract[112]|abstract[117]	new[112]|giv[117]	_	_
16-31	2524-2527	for	abstract[112]|abstract[117]	new[112]|giv[117]	_	_
16-32	2528-2532	NHEJ	abstract[112]|abstract[117]|abstract	new[112]|giv[117]|giv	coref	21-17
16-33	2533-2534	)	abstract[112]|abstract[117]	new[112]|giv[117]	_	_
16-34	2535-2537	do	_	_	_	_
16-35	2538-2541	not	_	_	_	_
16-36	2542-2547	cause	_	_	_	_
16-37	2548-2551	any	abstract[119]	giv[119]	coref	34-10[226_119]
16-38	2552-2558	viable	abstract[119]	giv[119]	_	_
16-39	2559-2568	syndromes	abstract[119]	giv[119]	_	_
16-40	2569-2571	in	_	_	_	_
16-41	2572-2578	humans	animal	new	_	_
16-42	2579-2580	(	_	_	_	_

#Text=Figure 1
17-1	2581-2587	Figure	abstract[121]	new[121]	_	_
17-2	2588-2589	1	abstract[121]	new[121]	_	_

#Text=) .
18-1	2590-2591	)	_	_	_	_
18-2	2592-2593	.	_	_	_	_

#Text=Recently , the delay in the radiation-induced nucleo-shuttling of ATM protein ( RIANS ) was shown to be a reliable parameter for predicting radiosensitivity and to provide a biologically relevant interpretation of the linear-quadratic model , the mathematical basis of the cellular radiation response .
19-1	2594-2602	Recently	_	_	_	_
19-2	2603-2604	,	_	_	_	_
19-3	2605-2608	the	abstract[122]	new[122]	coref	31-22[197_122]
19-4	2609-2614	delay	abstract[122]	new[122]	_	_
19-5	2615-2617	in	abstract[122]	new[122]	_	_
19-6	2618-2621	the	abstract[122]|substance[123]	new[122]|new[123]	_	_
19-7	2622-2639	radiation-induced	abstract[122]|substance[123]	new[122]|new[123]	_	_
19-8	2640-2656	nucleo-shuttling	abstract[122]|substance[123]	new[122]|new[123]	_	_
19-9	2657-2659	of	abstract[122]|substance[123]	new[122]|new[123]	_	_
19-10	2660-2663	ATM	abstract[122]|substance[123]|object|substance[125]	new[122]|new[123]|giv|giv[125]	coref	20-25
19-11	2664-2671	protein	abstract[122]|substance[123]|substance[125]	new[122]|new[123]|giv[125]	_	_
19-12	2672-2673	(	_	_	_	_
19-13	2674-2679	RIANS	abstract	new	coref	20-6
19-14	2680-2681	)	_	_	_	_
19-15	2682-2685	was	_	_	_	_
19-16	2686-2691	shown	_	_	_	_
19-17	2692-2694	to	_	_	_	_
19-18	2695-2697	be	_	_	_	_
19-19	2698-2699	a	abstract[127]	new[127]	_	_
19-20	2700-2708	reliable	abstract[127]	new[127]	_	_
19-21	2709-2718	parameter	abstract[127]	new[127]	_	_
19-22	2719-2722	for	abstract[127]	new[127]	_	_
19-23	2723-2733	predicting	abstract[127]	new[127]	_	_
19-24	2734-2750	radiosensitivity	abstract[127]|abstract	new[127]|giv	coref	24-7[165_0]
19-25	2751-2754	and	abstract[127]	new[127]	_	_
19-26	2755-2757	to	abstract[127]	new[127]	_	_
19-27	2758-2765	provide	abstract[127]	new[127]	_	_
19-28	2766-2767	a	abstract[127]|abstract[129]	new[127]|new[129]	_	_
19-29	2768-2780	biologically	abstract[127]|abstract[129]	new[127]|new[129]	_	_
19-30	2781-2789	relevant	abstract[127]|abstract[129]	new[127]|new[129]	_	_
19-31	2790-2804	interpretation	abstract[127]|abstract[129]	new[127]|new[129]	_	_
19-32	2805-2807	of	abstract[127]|abstract[129]	new[127]|new[129]	_	_
19-33	2808-2811	the	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	appos	19-37[131_130]
19-34	2812-2828	linear-quadratic	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	_	_
19-35	2829-2834	model	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	_	_
19-36	2835-2836	,	_	_	_	_
19-37	2837-2840	the	abstract[131]	giv[131]	coref	20-5[136_131]
19-38	2841-2853	mathematical	abstract[131]	giv[131]	_	_
19-39	2854-2859	basis	abstract[131]	giv[131]	_	_
19-40	2860-2862	of	abstract[131]	giv[131]	_	_
19-41	2863-2866	the	abstract[131]|abstract[133]	giv[131]|giv[133]	coref	34-44[235_133]
19-42	2867-2875	cellular	abstract[131]|abstract[133]	giv[131]|giv[133]	_	_
19-43	2876-2885	radiation	abstract[131]|abstract|abstract[133]	giv[131]|giv|giv[133]	_	_
19-44	2886-2894	response	abstract[131]|abstract[133]	giv[131]|giv[133]	_	_
19-45	2895-2896	.	_	_	_	_

#Text=In the context of the RIANS model , the following mechanistic hypothesis has been proposed : after irradiation , cytoplasmic trans-auto-phosphorylated dimeric forms of ATM become monomeric and diffuse to the nucleus .
20-1	2897-2899	In	_	_	_	_
20-2	2900-2903	the	abstract[134]	new[134]	_	_
20-3	2904-2911	context	abstract[134]	new[134]	_	_
20-4	2912-2914	of	abstract[134]	new[134]	_	_
20-5	2915-2918	the	abstract[134]|abstract[136]	new[134]|giv[136]	coref	34-18[230_136]
20-6	2919-2924	RIANS	abstract[134]|abstract|abstract[136]	new[134]|giv|giv[136]	coref	30-21[186_0]
20-7	2925-2930	model	abstract[134]|abstract[136]	new[134]|giv[136]	_	_
20-8	2931-2932	,	_	_	_	_
20-9	2933-2936	the	abstract[137]	giv[137]	_	_
20-10	2937-2946	following	abstract[137]	giv[137]	_	_
20-11	2947-2958	mechanistic	abstract[137]	giv[137]	_	_
20-12	2959-2969	hypothesis	abstract[137]	giv[137]	_	_
20-13	2970-2973	has	_	_	_	_
20-14	2974-2978	been	_	_	_	_
20-15	2979-2987	proposed	_	_	_	_
20-16	2988-2989	:	_	_	_	_
20-17	2990-2995	after	_	_	_	_
20-18	2996-3007	irradiation	event	giv	_	_
20-19	3008-3009	,	_	_	_	_
20-20	3010-3021	cytoplasmic	abstract[140]	new[140]	coref	35-16[240_140]
20-21	3022-3047	trans-auto-phosphorylated	abstract[140]	new[140]	_	_
20-22	3048-3055	dimeric	person|abstract[140]	new|new[140]	_	_
20-23	3056-3061	forms	abstract[140]	new[140]	_	_
20-24	3062-3064	of	abstract[140]	new[140]	_	_
20-25	3065-3068	ATM	abstract[140]|object	new[140]|giv	coref	21-6
20-26	3069-3075	become	_	_	_	_
20-27	3076-3085	monomeric	_	_	_	_
20-28	3086-3089	and	_	_	_	_
20-29	3090-3097	diffuse	_	_	_	_
20-30	3098-3100	to	_	_	_	_
20-31	3101-3104	the	object[142]	giv[142]	coref	21-2[143_142]
20-32	3105-3112	nucleus	object[142]	giv[142]	_	_
20-33	3113-3114	.	_	_	_	_

#Text=In the nucleus , active ATM monomers phosphorylate H2AX molecules at DSB sites , which activates NHEJ .
21-1	3115-3117	In	_	_	_	_
21-2	3118-3121	the	object[143]	giv[143]	coref	23-3[0_143]
21-3	3122-3129	nucleus	object[143]	giv[143]	_	_
21-4	3130-3131	,	_	_	_	_
21-5	3132-3138	active	person[145]	new[145]	coref	22-1[152_145]
21-6	3139-3142	ATM	object|person[145]	giv|new[145]	coref	22-2
21-7	3143-3151	monomers	person[145]	new[145]	_	_
21-8	3152-3165	phosphorylate	_	_	_	_
21-9	3166-3170	H2AX	abstract|object[147]	giv|new[147]	_	_
21-10	3171-3180	molecules	object[147]	new[147]	_	_
21-11	3181-3183	at	_	_	_	_
21-12	3184-3187	DSB	abstract|place[149]	giv|new[149]	coref	22-8
21-13	3188-3193	sites	place[149]	new[149]	_	_
21-14	3194-3195	,	place[149]	new[149]	_	_
21-15	3196-3201	which	place[149]	new[149]	_	_
21-16	3202-3211	activates	place[149]	new[149]	_	_
21-17	3212-3216	NHEJ	place[149]|abstract	new[149]|giv	_	_
21-18	3217-3218	.	_	_	_	_

#Text=The ATM monomers will re-dimerize during the DSB repair process .
22-1	3219-3222	The	person[152]	giv[152]	_	_
22-2	3223-3226	ATM	object|person[152]	giv|giv[152]	coref	23-5
22-3	3227-3235	monomers	person[152]	giv[152]	_	_
22-4	3236-3240	will	_	_	_	_
22-5	3241-3252	re-dimerize	_	_	_	_
22-6	3253-3259	during	_	_	_	_
22-7	3260-3263	the	event[155]	new[155]	_	_
22-8	3264-3267	DSB	abstract|abstract[154]|event[155]	giv|giv[154]|new[155]	coref|coref	33-24|33-24[214_154]
22-9	3268-3274	repair	abstract[154]|event[155]	giv[154]|new[155]	_	_
22-10	3275-3282	process	event[155]	new[155]	_	_
22-11	3283-3284	.	_	_	_	_

#Text=Once in nucleus , ATM may also inhibit MRE11 nuclease activity or any other actor responsible for genomic instability .
23-1	3285-3289	Once	_	_	_	_
23-2	3290-3292	in	_	_	_	_
23-3	3293-3300	nucleus	object	giv	_	_
23-4	3301-3302	,	_	_	_	_
23-5	3303-3306	ATM	object	giv	coref	24-11
23-6	3307-3310	may	_	_	_	_
23-7	3311-3315	also	_	_	_	_
23-8	3316-3323	inhibit	_	_	_	_
23-9	3324-3329	MRE11	abstract|abstract[160]	new|new[160]	_	_
23-10	3330-3338	nuclease	event|abstract[160]	new|new[160]	_	_
23-11	3339-3347	activity	abstract[160]	new[160]	_	_
23-12	3348-3350	or	_	_	_	_
23-13	3351-3354	any	abstract[161]	new[161]	_	_
23-14	3355-3360	other	abstract[161]	new[161]	_	_
23-15	3361-3366	actor	abstract[161]	new[161]	_	_
23-16	3367-3378	responsible	abstract[161]	new[161]	_	_
23-17	3379-3382	for	abstract[161]	new[161]	_	_
23-18	3383-3390	genomic	abstract[161]|abstract[162]	new[161]|new[162]	_	_
23-19	3391-3402	instability	abstract[161]|abstract[162]	new[161]|new[162]	_	_
23-20	3403-3404	.	_	_	_	_

#Text=By contrast , in cells with moderate radiosensitivity , over-expressed ATM substrates may delay the RIANS , thereby favoring cancer proneness and aging .
24-1	3405-3407	By	_	_	_	_
24-2	3408-3416	contrast	abstract	giv	_	_
24-3	3417-3418	,	_	_	_	_
24-4	3419-3421	in	_	_	_	_
24-5	3422-3427	cells	object[164]	giv[164]	_	_
24-6	3428-3432	with	object[164]	giv[164]	_	_
24-7	3433-3441	moderate	object[164]|abstract[165]	giv[164]|giv[165]	coref	29-4[0_165]
24-8	3442-3458	radiosensitivity	object[164]|abstract[165]	giv[164]|giv[165]	_	_
24-9	3459-3460	,	_	_	_	_
24-10	3461-3475	over-expressed	substance[167]	new[167]	coref	31-34[201_167]
24-11	3476-3479	ATM	object|substance[167]	giv|new[167]	coref	31-32
24-12	3480-3490	substrates	substance[167]	new[167]	_	_
24-13	3491-3494	may	_	_	_	_
24-14	3495-3500	delay	_	_	_	_
24-15	3501-3504	the	abstract[168]	new[168]	coref	31-25[198_168]
24-16	3505-3510	RIANS	abstract[168]	new[168]	_	_
24-17	3511-3512	,	_	_	_	_
24-18	3513-3520	thereby	_	_	_	_
24-19	3521-3529	favoring	_	_	_	_
24-20	3530-3536	cancer	abstract|abstract[170]|abstract[171]	giv|giv[170]|new[171]	coref|coref|coref	30-37|33-40[220_170]|33-40[221_171]
24-21	3537-3546	proneness	abstract[170]|abstract[171]	giv[170]|new[171]	_	_
24-22	3547-3550	and	abstract[171]	new[171]	_	_
24-23	3551-3556	aging	abstract[171]|abstract	new[171]|new	ana	25-1
24-24	3557-3558	.	_	_	_	_

#Text=This is notably the case for huntingtin , neurofibromin , and tuberin .
25-1	3559-3563	This	abstract	giv	coref	25-3[174_0]
25-2	3564-3566	is	_	_	_	_
25-3	3567-3574	notably	abstract[174]	giv[174]	coref	33-45[222_174]
25-4	3575-3578	the	abstract[174]	giv[174]	_	_
25-5	3579-3583	case	abstract[174]	giv[174]	_	_
25-6	3584-3587	for	abstract[174]	giv[174]	_	_
25-7	3588-3598	huntingtin	abstract[174]|animal	giv[174]|new	_	_
25-8	3599-3600	,	abstract[174]	giv[174]	_	_
25-9	3601-3614	neurofibromin	abstract[174]|abstract	giv[174]|new	_	_
25-10	3615-3616	,	abstract[174]	giv[174]	_	_
25-11	3617-3620	and	abstract[174]	giv[174]	_	_
25-12	3621-3628	tuberin	abstract[174]|substance	giv[174]|new	_	_
25-13	3629-3630	.	_	_	_	_

#Text=(
26-1	3631-3632	(	_	_	_	_

#Text=Figure 6
27-1	3633-3639	Figure	abstract[178]	new[178]	_	_
27-2	3640-3641	6	abstract[178]	new[178]	_	_

#Text=) .
28-1	3642-3643	)	_	_	_	_
28-2	3644-3645	.	_	_	_	_

#Text=Three groups of radiosensitivity have been defined :
29-1	3646-3651	Three	abstract[179]	new[179]	_	_
29-2	3652-3658	groups	abstract[179]	new[179]	_	_
29-3	3659-3661	of	abstract[179]	new[179]	_	_
29-4	3662-3678	radiosensitivity	abstract[179]|abstract	new[179]|giv	coref	31-18[196_0]
29-5	3679-3683	have	_	_	_	_
29-6	3684-3688	been	_	_	_	_
29-7	3689-3696	defined	_	_	_	_
29-8	3697-3698	:	_	_	_	_

#Text=Group I ( about 75 % to 85 % whole population ) represents the normosensitive ( radioresistant ) patients with a rapid RIANS after 2 Gy , a low risk of post-radiotherapy tissue reaction and of cancer
30-1	3699-3704	Group	person[181]	new[181]	appos	30-4[184_181]
30-2	3705-3706	I	person[181]	new[181]	_	_
30-3	3707-3708	(	_	_	_	_
30-4	3709-3714	about	abstract[182]|person[184]	new[182]|giv[184]	coref	31-1[192_184]
30-5	3715-3717	75	abstract[182]|person[184]	new[182]|giv[184]	_	_
30-6	3718-3719	%	abstract[182]|person[184]	new[182]|giv[184]	_	_
30-7	3720-3722	to	abstract[182]|person[184]	new[182]|giv[184]	_	_
30-8	3723-3725	85	abstract[182]|abstract[183]|person[184]	new[182]|new[183]|giv[184]	_	_
30-9	3726-3727	%	abstract[182]|abstract[183]|person[184]	new[182]|new[183]|giv[184]	_	_
30-10	3728-3733	whole	person[184]	giv[184]	_	_
30-11	3734-3744	population	person[184]	giv[184]	_	_
30-12	3745-3746	)	_	_	_	_
30-13	3747-3757	represents	_	_	_	_
30-14	3758-3761	the	person[185]	new[185]	coref	31-14[195_185]
30-15	3762-3776	normosensitive	person[185]	new[185]	_	_
30-16	3777-3778	(	person[185]	new[185]	_	_
30-17	3779-3793	radioresistant	person[185]	new[185]	_	_
30-18	3794-3795	)	person[185]	new[185]	_	_
30-19	3796-3804	patients	person[185]	new[185]	_	_
30-20	3805-3809	with	person[185]	new[185]	_	_
30-21	3810-3811	a	person[185]|abstract[186]	new[185]|giv[186]	coref	34-19[0_186]
30-22	3812-3817	rapid	person[185]|abstract[186]	new[185]|giv[186]	_	_
30-23	3818-3823	RIANS	person[185]|abstract[186]	new[185]|giv[186]	_	_
30-24	3824-3829	after	person[185]|abstract[186]	new[185]|giv[186]	_	_
30-25	3830-3831	2	person[185]|abstract[186]|time[187]	new[185]|giv[186]|new[187]	_	_
30-26	3832-3834	Gy	person[185]|abstract[186]|time[187]	new[185]|giv[186]|new[187]	_	_
30-27	3835-3836	,	_	_	_	_
30-28	3837-3838	a	abstract[188]	new[188]	_	_
30-29	3839-3842	low	abstract[188]	new[188]	_	_
30-30	3843-3847	risk	abstract[188]	new[188]	_	_
30-31	3848-3850	of	abstract[188]	new[188]	_	_
30-32	3851-3868	post-radiotherapy	abstract[188]|event[190]	new[188]|new[190]	_	_
30-33	3869-3875	tissue	abstract[188]|object|event[190]	new[188]|new|new[190]	_	_
30-34	3876-3884	reaction	abstract[188]|event[190]	new[188]|new[190]	_	_
30-35	3885-3888	and	abstract[188]	new[188]	_	_
30-36	3889-3891	of	abstract[188]	new[188]	_	_
30-37	3892-3898	cancer	abstract[188]|abstract	new[188]|giv	coref	32-13

#Text=Group II ( about 5 – 20 % of whole population ) represents the patients who elicit a moderate radiosensitivity with a delay in the RIANS due to the sequestration of ATM by mutated and over-expressed substrates .
31-1	3899-3904	Group	person[192]	giv[192]	coref	31-10[194_192]
31-2	3905-3907	II	person[192]	giv[192]	_	_
31-3	3908-3909	(	_	_	_	_
31-4	3910-3915	about	abstract[193]	new[193]	coref	33-4[207_193]
31-5	3916-3917	5	abstract[193]	new[193]	_	_
31-6	3918-3919	–	abstract[193]	new[193]	_	_
31-7	3920-3922	20	abstract[193]	new[193]	_	_
31-8	3923-3924	%	abstract[193]	new[193]	_	_
31-9	3925-3927	of	abstract[193]	new[193]	_	_
31-10	3928-3933	whole	abstract[193]|person[194]	new[193]|giv[194]	coref	33-4[208_194]
31-11	3934-3944	population	abstract[193]|person[194]	new[193]|giv[194]	_	_
31-12	3945-3946	)	_	_	_	_
31-13	3947-3957	represents	_	_	_	_
31-14	3958-3961	the	person[195]	giv[195]	coref	32-1[202_195]
31-15	3962-3970	patients	person[195]	giv[195]	_	_
31-16	3971-3974	who	person[195]	giv[195]	_	_
31-17	3975-3981	elicit	person[195]	giv[195]	_	_
31-18	3982-3983	a	person[195]|abstract[196]	giv[195]|giv[196]	coref	34-7[225_196]
31-19	3984-3992	moderate	person[195]|abstract[196]	giv[195]|giv[196]	_	_
31-20	3993-4009	radiosensitivity	person[195]|abstract[196]	giv[195]|giv[196]	_	_
31-21	4010-4014	with	person[195]|abstract[196]	giv[195]|giv[196]	_	_
31-22	4015-4016	a	person[195]|abstract[196]|abstract[197]	giv[195]|giv[196]|giv[197]	_	_
31-23	4017-4022	delay	person[195]|abstract[196]|abstract[197]	giv[195]|giv[196]|giv[197]	_	_
31-24	4023-4025	in	person[195]|abstract[196]|abstract[197]	giv[195]|giv[196]|giv[197]	_	_
31-25	4026-4029	the	person[195]|abstract[196]|abstract[197]|abstract[198]	giv[195]|giv[196]|giv[197]|giv[198]	_	_
31-26	4030-4035	RIANS	person[195]|abstract[196]|abstract[197]|abstract[198]	giv[195]|giv[196]|giv[197]|giv[198]	_	_
31-27	4036-4039	due	person[195]|abstract[196]	giv[195]|giv[196]	_	_
31-28	4040-4042	to	person[195]|abstract[196]	giv[195]|giv[196]	_	_
31-29	4043-4046	the	person[195]|abstract[196]|event[199]	giv[195]|giv[196]|new[199]	_	_
31-30	4047-4060	sequestration	person[195]|abstract[196]|event[199]	giv[195]|giv[196]|new[199]	_	_
31-31	4061-4063	of	person[195]|abstract[196]|event[199]	giv[195]|giv[196]|new[199]	_	_
31-32	4064-4067	ATM	person[195]|abstract[196]|event[199]|object	giv[195]|giv[196]|new[199]|giv	coref	33-11
31-33	4068-4070	by	person[195]|abstract[196]|event[199]	giv[195]|giv[196]|new[199]	_	_
31-34	4071-4078	mutated	person[195]|abstract[196]|event[199]|substance[201]	giv[195]|giv[196]|new[199]|giv[201]	_	_
31-35	4079-4082	and	person[195]|abstract[196]|event[199]|substance[201]	giv[195]|giv[196]|new[199]|giv[201]	_	_
31-36	4083-4097	over-expressed	person[195]|abstract[196]|event[199]|substance[201]	giv[195]|giv[196]|new[199]|giv[201]	_	_
31-37	4098-4108	substrates	person[195]|abstract[196]|event[199]|substance[201]	giv[195]|giv[196]|new[199]|giv[201]	_	_
31-38	4109-4110	.	_	_	_	_

#Text=These patients are moderately radiosensitive and may have a high risk of cancer or neurodegeneration .
32-1	4111-4116	These	person[202]	giv[202]	coref	33-10[210_202]
32-2	4117-4125	patients	person[202]	giv[202]	_	_
32-3	4126-4129	are	_	_	_	_
32-4	4130-4140	moderately	_	_	_	_
32-5	4141-4155	radiosensitive	_	_	_	_
32-6	4156-4159	and	_	_	_	_
32-7	4160-4163	may	_	_	_	_
32-8	4164-4168	have	_	_	_	_
32-9	4169-4170	a	abstract[203]	new[203]	_	_
32-10	4171-4175	high	abstract[203]	new[203]	_	_
32-11	4176-4180	risk	abstract[203]	new[203]	_	_
32-12	4181-4183	of	abstract[203]	new[203]	_	_
32-13	4184-4190	cancer	abstract[203]|abstract	new[203]|giv	coref	33-42
32-14	4191-4193	or	abstract[203]	new[203]	_	_
32-15	4194-4211	neurodegeneration	abstract[203]|abstract	new[203]|new	_	_
32-16	4212-4213	.	_	_	_	_

#Text=Group III ( <1 % whole population ) represents the ATM -mutated patients with no functional ATM kinase or those who show strong DSB repair defects ( like the LIG4 -mutated patient described above ) , hyper-radiosensitivity , and either high cancer proneness or severe accelerated aging .
33-1	4214-4219	Group	abstract[206]	new[206]	_	_
33-2	4220-4223	III	abstract[206]	new[206]	_	_
33-3	4224-4225	(	_	_	_	_
33-4	4226-4228	<1	abstract[207]|person[208]	giv[207]|giv[208]	_	_
33-5	4229-4230	%	abstract[207]|person[208]	giv[207]|giv[208]	_	_
33-6	4231-4236	whole	person[208]	giv[208]	_	_
33-7	4237-4247	population	person[208]	giv[208]	_	_
33-8	4248-4249	)	_	_	_	_
33-9	4250-4260	represents	_	_	_	_
33-10	4261-4264	the	person[210]	giv[210]	_	_
33-11	4265-4268	ATM	object|person[210]	giv|giv[210]	coref	33-17
33-12	4269-4277	-mutated	person[210]	giv[210]	_	_
33-13	4278-4286	patients	person[210]	giv[210]	_	_
33-14	4287-4291	with	person[210]	giv[210]	_	_
33-15	4292-4294	no	person[210]|abstract[212]	giv[210]|new[212]	_	_
33-16	4295-4305	functional	person[210]|abstract[212]	giv[210]|new[212]	_	_
33-17	4306-4309	ATM	person[210]|object|abstract[212]	giv[210]|giv|new[212]	coref	34-32
33-18	4310-4316	kinase	person[210]|abstract[212]	giv[210]|new[212]	_	_
33-19	4317-4319	or	person[210]	giv[210]	_	_
33-20	4320-4325	those	person[210]	giv[210]	_	_
33-21	4326-4329	who	person[210]	giv[210]	_	_
33-22	4330-4334	show	person[210]	giv[210]	_	_
33-23	4335-4341	strong	person[210]|abstract[215]	giv[210]|new[215]	_	_
33-24	4342-4345	DSB	person[210]|abstract|abstract[214]|abstract[215]	giv[210]|giv|giv[214]|new[215]	coref|coref	35-26|35-26[244_214]
33-25	4346-4352	repair	person[210]|abstract[214]|abstract[215]	giv[210]|giv[214]|new[215]	_	_
33-26	4353-4360	defects	person[210]|abstract[215]	giv[210]|new[215]	_	_
33-27	4361-4362	(	person[210]|abstract[215]	giv[210]|new[215]	_	_
33-28	4363-4367	like	person[210]|abstract[215]	giv[210]|new[215]	_	_
33-29	4368-4371	the	person[210]|abstract[215]|person[217]	giv[210]|new[215]|new[217]	_	_
33-30	4372-4376	LIG4	person[210]|abstract[215]|abstract|person[217]	giv[210]|new[215]|giv|new[217]	_	_
33-31	4377-4385	-mutated	person[210]|abstract[215]|person[217]	giv[210]|new[215]|new[217]	_	_
33-32	4386-4393	patient	person[210]|abstract[215]|person[217]	giv[210]|new[215]|new[217]	_	_
33-33	4394-4403	described	person[210]|abstract[215]|person[217]	giv[210]|new[215]|new[217]	_	_
33-34	4404-4409	above	person[210]|abstract[215]|person[217]	giv[210]|new[215]|new[217]	_	_
33-35	4410-4411	)	person[210]|abstract[215]	giv[210]|new[215]	_	_
33-36	4412-4413	,	person[210]	giv[210]	_	_
33-37	4414-4436	hyper-radiosensitivity	person[210]|abstract	giv[210]|giv	_	_
33-38	4437-4438	,	person[210]	giv[210]	_	_
33-39	4439-4442	and	person[210]	giv[210]	_	_
33-40	4443-4449	either	person[210]|abstract[220]|abstract[221]	giv[210]|giv[220]|giv[221]	ana	34-2[0_220]
33-41	4450-4454	high	person[210]|abstract[220]|abstract[221]	giv[210]|giv[220]|giv[221]	_	_
33-42	4455-4461	cancer	person[210]|abstract|abstract[220]|abstract[221]	giv[210]|giv|giv[220]|giv[221]	_	_
33-43	4462-4471	proneness	person[210]|abstract[220]|abstract[221]	giv[210]|giv[220]|giv[221]	_	_
33-44	4472-4474	or	person[210]|abstract[221]	giv[210]|giv[221]	_	_
33-45	4475-4481	severe	person[210]|abstract[221]|abstract[222]	giv[210]|giv[221]|giv[222]	_	_
33-46	4482-4493	accelerated	person[210]|abstract[221]|abstract[222]	giv[210]|giv[221]|giv[222]	_	_
33-47	4494-4499	aging	person[210]|abstract[221]|abstract[222]	giv[210]|giv[221]|giv[222]	_	_
33-48	4500-4501	.	_	_	_	_

#Text=While it provides relevant explanation of the radiosensitivity of syndromes caused by mutations of cytoplasmic proteins , the RIANS model appears to be compatible with all the alternative models , as ATM is upstream of all the cascades of radiation-induced phosphorylations involved in the individual response to IR .
34-1	4502-4507	While	_	_	_	_
34-2	4508-4510	it	abstract	giv	_	_
34-3	4511-4519	provides	_	_	_	_
34-4	4520-4528	relevant	abstract[224]	new[224]	_	_
34-5	4529-4540	explanation	abstract[224]	new[224]	_	_
34-6	4541-4543	of	abstract[224]	new[224]	_	_
34-7	4544-4547	the	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-8	4548-4564	radiosensitivity	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-9	4565-4567	of	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-10	4568-4577	syndromes	abstract[224]|abstract[225]|abstract[226]	new[224]|giv[225]|giv[226]	_	_
34-11	4578-4584	caused	abstract[224]|abstract[225]|abstract[226]	new[224]|giv[225]|giv[226]	_	_
34-12	4585-4587	by	abstract[224]|abstract[225]|abstract[226]	new[224]|giv[225]|giv[226]	_	_
34-13	4588-4597	mutations	abstract[224]|abstract[225]|abstract[226]|abstract[227]	new[224]|giv[225]|giv[226]|new[227]	_	_
34-14	4598-4600	of	abstract[224]|abstract[225]|abstract[226]|abstract[227]	new[224]|giv[225]|giv[226]|new[227]	_	_
34-15	4601-4612	cytoplasmic	abstract[224]|abstract[225]|abstract[226]|abstract[227]|substance[228]	new[224]|giv[225]|giv[226]|new[227]|new[228]	_	_
34-16	4613-4621	proteins	abstract[224]|abstract[225]|abstract[226]|abstract[227]|substance[228]	new[224]|giv[225]|giv[226]|new[227]|new[228]	_	_
34-17	4622-4623	,	_	_	_	_
34-18	4624-4627	the	abstract[230]	giv[230]	_	_
34-19	4628-4633	RIANS	abstract|abstract[230]	giv|giv[230]	_	_
34-20	4634-4639	model	abstract[230]	giv[230]	_	_
34-21	4640-4647	appears	_	_	_	_
34-22	4648-4650	to	_	_	_	_
34-23	4651-4653	be	_	_	_	_
34-24	4654-4664	compatible	_	_	_	_
34-25	4665-4669	with	_	_	_	_
34-26	4670-4673	all	abstract[231]	giv[231]	_	_
34-27	4674-4677	the	abstract[231]	giv[231]	_	_
34-28	4678-4689	alternative	abstract[231]	giv[231]	_	_
34-29	4690-4696	models	abstract[231]	giv[231]	_	_
34-30	4697-4698	,	_	_	_	_
34-31	4699-4701	as	_	_	_	_
34-32	4702-4705	ATM	object	giv	coref	35-17
34-33	4706-4708	is	_	_	_	_
34-34	4709-4717	upstream	_	_	_	_
34-35	4718-4720	of	_	_	_	_
34-36	4721-4724	all	abstract[233]	new[233]	_	_
34-37	4725-4728	the	abstract[233]	new[233]	_	_
34-38	4729-4737	cascades	abstract[233]	new[233]	_	_
34-39	4738-4740	of	abstract[233]	new[233]	_	_
34-40	4741-4758	radiation-induced	abstract[233]|abstract[234]	new[233]|new[234]	_	_
34-41	4759-4775	phosphorylations	abstract[233]|abstract[234]	new[233]|new[234]	_	_
34-42	4776-4784	involved	abstract[233]|abstract[234]	new[233]|new[234]	_	_
34-43	4785-4787	in	abstract[233]|abstract[234]	new[233]|new[234]	_	_
34-44	4788-4791	the	abstract[233]|abstract[234]|abstract[235]	new[233]|new[234]|giv[235]	_	_
34-45	4792-4802	individual	abstract[233]|abstract[234]|abstract[235]	new[233]|new[234]|giv[235]	_	_
34-46	4803-4811	response	abstract[233]|abstract[234]|abstract[235]	new[233]|new[234]|giv[235]	_	_
34-47	4812-4814	to	abstract[233]|abstract[234]|abstract[235]	new[233]|new[234]|giv[235]	_	_
34-48	4815-4817	IR	abstract[233]|abstract[234]|abstract[235]|abstract	new[233]|new[234]|giv[235]|new	_	_
34-49	4818-4819	.	_	_	_	_

#Text=Obviously , further investigations are needed to better understand the direct or indirect role of cytoplasmic ATM forms in the activation or the inhibition of DSB repair pathways .
35-1	4820-4829	Obviously	_	_	_	_
35-2	4830-4831	,	_	_	_	_
35-3	4832-4839	further	abstract[237]	new[237]	_	_
35-4	4840-4854	investigations	abstract[237]	new[237]	_	_
35-5	4855-4858	are	_	_	_	_
35-6	4859-4865	needed	_	_	_	_
35-7	4866-4868	to	_	_	_	_
35-8	4869-4875	better	_	_	_	_
35-9	4876-4886	understand	_	_	_	_
35-10	4887-4890	the	abstract[238]	new[238]	_	_
35-11	4891-4897	direct	abstract[238]	new[238]	_	_
35-12	4898-4900	or	abstract[238]	new[238]	_	_
35-13	4901-4909	indirect	abstract[238]	new[238]	_	_
35-14	4910-4914	role	abstract[238]	new[238]	_	_
35-15	4915-4917	of	abstract[238]	new[238]	_	_
35-16	4918-4929	cytoplasmic	abstract[238]|abstract[240]	new[238]|giv[240]	_	_
35-17	4930-4933	ATM	abstract[238]|object|abstract[240]	new[238]|giv|giv[240]	_	_
35-18	4934-4939	forms	abstract[238]|abstract[240]	new[238]|giv[240]	_	_
35-19	4940-4942	in	abstract[238]	new[238]	_	_
35-20	4943-4946	the	abstract[238]|event[241]	new[238]|new[241]	_	_
35-21	4947-4957	activation	abstract[238]|event[241]	new[238]|new[241]	_	_
35-22	4958-4960	or	abstract[238]	new[238]	_	_
35-23	4961-4964	the	abstract[238]|event[242]	new[238]|new[242]	_	_
35-24	4965-4975	inhibition	abstract[238]|event[242]	new[238]|new[242]	_	_
35-25	4976-4978	of	abstract[238]|event[242]	new[238]|new[242]	_	_
35-26	4979-4982	DSB	abstract[238]|event[242]|abstract|abstract[244]|abstract[245]	new[238]|new[242]|giv|giv[244]|new[245]	_	_
35-27	4983-4989	repair	abstract[238]|event[242]|abstract[244]|abstract[245]	new[238]|new[242]|giv[244]|new[245]	_	_
35-28	4990-4998	pathways	abstract[238]|event[242]|abstract[245]	new[238]|new[242]|new[245]	_	_
35-29	4999-5000	.	_	_	_	_
